Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EA3571 Phase 1 biomarker analysis in healthy males
jRCT1050230133Phase 1Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing EA3571 multiple-dose with Placebo (2 arms). Primary endpoint: Plasma hormone concentration. Started Dec 2023; status: completed.
02
Drugs
EA-3571
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT1050230133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1050230133.